Announcements
- Renovaro, Inc. Announces $10 million in Equity Committed
- Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
- Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
- RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
- Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
- Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
- Statement of Renovaro Inc
- Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
- AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
- Renovaro Biosciences Announces Results of Special Meeting of Shareholders
More ▼
Key statistics
On Tuesday, Renovaro Inc (2Q5:DEU) closed at 1.17, 165.16% above the 52 week low of 0.442 set on Jul 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.15 |
---|---|
High | 1.24 |
Low | 1.13 |
Bid | 1.19 |
Offer | 1.25 |
Previous close | 1.18 |
Average volume | 466.67 |
---|---|
Shares outstanding | 147.50m |
Free float | 109.86m |
P/E (TTM) | -- |
Market cap | 196.18m USD |
EPS (TTM) | -0.7661 USD |
Data delayed at least 15 minutes, as of Jul 23 2024.
More ▼